Final overall survival analysis from the phase 3 INAVO120 study demonstrates that first-line inavolisib in combination with standard-of care palbociclib-fulvestrant…
NEJM
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…
The New England Journal of Medicine publishes today the results of the SUNLIGHT study, a Phase III clinical trial comparing…
